Based on extrapolated survival data from the IMspire150 trial, treating patients with newly diagnosed unresectable locally advanced or metastatic BRAF V600 variation melanoma with vemurafenib plus cobimetinib was associated with a lifetime expected cost of $1 205 321 for an expected gain of 5.733 LYs per patient. Here, BRAF is linked to melanoma.